B of A Securities analyst Alec Stranahan upgrades Novavax (NASDAQ:NVAX) from Underperform to Neutral and raises the price target from $4 to $12.
B of A Securities Upgrades Novavax to Neutral, Raises Price Target to $12
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.